J.T. Hartmann

5.9k citations

76 papers · 3.5k indexed · 1 hit paper · h-index 31

Impact in

Oncology top 2%
- Colorectal Cancer Treatments and Studies
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Gastroenterology 8
- Gastrointestinal Tumor Research and Treatment 8
Pulmonary and Respiratory Medicine 39
- Sarcoma Diagnosis and Treatment 15
- Gastric Cancer Management and Outcomes 11
- Lung Cancer Treatments and Mutations 6

Co-authors: Carsten Bokemeyer Lothar Kanz Christian Kollmannsberger Hans‐Joachim Schmoll P. Koralewski Igor Bondarenko İ. Çelik Filippo de Braud
Journals: Journal of Clinical Oncology (23 papers)Annals of Oncology (11 papers)British Journal of Cancer (6 papers)European Journal of Cancer (6 papers)World Journal of Urology (4 papers)
Partner nations: Germany United States France

In The Last Decade

J.T. Hartmann

70 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study 2011 · 612 citations

Peers

Countries citing papers authored by J.T. Hartmann

Since Specialization

Citations

This map shows the geographic impact of J.T. Hartmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.T. Hartmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.T. Hartmann more than expected).

Fields of papers citing papers by J.T. Hartmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.T. Hartmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.T. Hartmann. The network helps show where J.T. Hartmann may publish in the future.

Co-authors

The 25 scholars most cited alongside J.T. Hartmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.T. Hartmann Line = papers co-authored together J.T. Hartmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Glioblastoma targeting by water-soluble hypericin derivate HHL-PVP and photodynamic tumour killing Biomedicine & Pharmacotherapy ·今井翔, Andreas Kubin, Karoline Fechter, Hinostroza Mejía, J.T. Hartmann, Karl-Heinz Stanzel, Branislav Radović, Genrikh S. Ritter, Muammer Üçal, Stefan Ropele, Christoph Bückle, Mario Mischkulnig, S.C. Felter, Bernadette Liegl‐Atzwanger, Lionel Wightman, Beate Rinner	2025	0
2	Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors Annals of Oncology ·Christophe Massard, A. Kramar, J. Beyer, J.T. Hartmann, Anja Lorch, J L Pico, Giovanni Rosti, Jean‐Pierre Droz, Karim Fizazi	2012	23
3	A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer Investigational New Drugs ·J.T. Hartmann, Christian Kollmannsberger, Ingolf Cascorbi, Frank Mayer, Marcus M. Schittenhelm, S. Heeger, Carsten Bokemeyer	2012	7
4	Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study Annals of Oncology ·Karin Oechsle, Friedemann Honecker, Tina Cheng, Frank Mayer, Piotr Czaykowski, Eric Winquist, Lori Wood, Martin Fenner, Daniel Sibony, J.T. Hartmann, K.N. Chi, Carsten Bokemeyer, Christian Kollmannsberger	2011	72
5	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Annals of Oncology ·Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann, Filippo de Braud, Gunter Schuch, Angela Zubel, İ. Çelik, M. Schlichting, P. Koralewski Hit paper breakdown →	2011	612
6	An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer European Journal of Cancer ·Markus Moehler, Annett Mueller, J.T. Hartmann, M. Ebert, Salah‐Eddin Al‐Batran, Peter Reimer, Martin R. Weihrauch, Florian Lordick, Tanja Trarbach, Stefan Biesterfeld, Maria Kabisch, Daniel Wachtlin, Peter R. Galle	2011	73
7	Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial European journal of medical research ·M. Schlemmer, Sebastian Bauer, 吴正桥, J.T. Hartmann, Carsten Bokemeyer, Christian Hosius, Peter Reichardt	2011	25
8	Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion Annals of Oncology ·Karin Potthoff, Ralf‐Dieter Hofheinz, Jessica C. Hassel, Matthias Volkenandt, Florian Lordick, J.T. Hartmann, Meinolf Karthaus, Hanno Riess, Hans‐Peter Lipp, Axel Hauschild, Tanja Trarbach, Andreas Wollenberg	2010	86
9	Myocardial infarction and other major vascular events during chemotherapy for testicular cancer Annals of Oncology ·Klaus‐Peter Dieckmann, A. Gerl, Julian Witt, J.T. Hartmann	2010	49
10	High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors Annals of Oncology ·Anja Lorch, Andreas Neubauer, ROSÂNGELA MARIA ARAUJO TELES, Annette Dieing, J.T. Hartmann, Oliver Rick, Carsten Bokemeyer, J. Beyer	2009	42
11	Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: Evaluation of a prognostic score for survival after high-dose chemotherapy European Journal of Cancer ·DR. JUSTIN MGBECHI ODINIOHA GABRIEL, J. Beyer, Carsten Bokemeyer, J.T. Hartmann, Oliver Rick	2007	9
12	Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO Annals of Oncology ·Christian Kollmannsberger, Wilfried Budach, M. Stahl, N. Schleucher, Thomas Hehr, H. Wilke, Jan Schleicher, U. Vanhoefer, E. C. Jehle, Karin Oechsle, Tanja Trarbach, L. H. Rohrs, Lothar Kanz, J.T. Hartmann, Carsten Bokemeyer	2005	31
13	Hypersensitivity pneumonitis associated with the use of trofosfamide Anti-Cancer Drugs ·Hans‐Georg Kopp, Lothar Kanz, J.T. Hartmann	2004	3
14	The role of [18F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors?prospects for management World Journal of Urology ·A. H. de Klerck, Karin Oechsle, Carsten Bokemeyer, Christian Kollmannsberger, Ik Soo Lee, Roland Bares, J.T. Hartmann, Reinhard Vonthein, Shuanghao Yang	2004	33
15	A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer British Journal of Cancer ·Christian Kollmannsberger, D. Quietzsch, Christian Haag, Thomas Lingenfelser, M. Schroeder, J.T. Hartmann, Thiadens Aa, 直樹定月, Michael Clemens, Lothar Kanz, Carsten Bokemeyer	2000	101
16	Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients British Journal of Cancer ·M.A. Kuczyk, S. Machtens, Monika Sóley Skarphéðinsdóttir, A. E. R. Boak, Whitney V. Christian, Ruth Knüchel, J.T. Hartmann, Carsten Bokemeyer, Udo Jonas, Jürgen Serth	1999	40
17	Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases European Journal of Cancer ·J.T. Hartmann, Hans‐Joachim Schmoll, Carsten Bokemeyer, R. Féty, Catherine Lucas, B. Giroux	1998	4
18	Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies Journal of Cancer Research and Clinical Oncology ·Christian Kollmannsberger, J.T. Hartmann, Lothar Kanz, Carsten Bokemeyer	1998	75
19	Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. Journal of Clinical Oncology ·Christian Kollmannsberger, J. Beyer, Jean‐Pierre Droz, A. Harstrick, J.T. Hartmann, Pierre Biron, Aude Fléchon, Patrick Schöffski, M.A. Kuczyk, Hans‐Joachim Schmoll, Lothar Kanz, Carsten Bokemeyer	1998	143
20	Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours European Journal of Cancer ·J.T. Hartmann, Myrna Candelaria, M. Kuczyk, Hans‐Joachim Schmoll, Carsten Bokemeyer	1997	64

About J.T. Hartmann

J.T. Hartmann is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Hematology, Oncology and Reproductive Medicine, having authored 76 papers that have together received 3.5k indexed citations. Recurring topics across this work include Testicular diseases and treatments (28 papers), Colorectal Cancer Treatments and Studies (15 papers), Sarcoma Diagnosis and Treatment (15 papers), Gastric Cancer Management and Outcomes (11 papers), Neuroblastoma Research and Treatments (11 papers), Multiple Myeloma Research and Treatments (9 papers), Gastrointestinal Tumor Research and Treatment (8 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Oncology (1.5k citations), Hepatology (367 citations), Reproductive Medicine (346 citations), Pulmonary and Respiratory Medicine (1.3k citations) and Gastroenterology (193 citations). J.T. Hartmann has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Carsten Bokemeyer, Lothar Kanz, Christian Kollmannsberger, Hans‐Joachim Schmoll, P. Koralewski, Igor Bondarenko, İ. Çelik, Filippo de Braud, Angela Zubel and Gunter Schuch. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer and World Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact